



The global malaria portfolio: where we stand today

David Reddy PhD, CEO MMV

Defeating Malaria Together




MMV strategic priorities 2015-2018

from control to eradication



376 partners spanning the world



including:

28 pharmaceuticals companies

13 biotech companies


56 universities

38 research institutes

72 clinical sites


50 government agencies

5 (+2) medicines launched from 2009-2015



* Transferred from DNDi-led partnership portfolio to MMV-led partnership portfolio 20th May 2015

SERCaP



**single encounter radical cure
and prophylaxis**

9 new medicines

in clinical development

Pyramax-granules (Filed)

Eurartesim-dispersible (Phase III)

Rectal artesunate (Phase IIIb)

Tafenoquine (Phase III)

OZ439/PQP (Phase IIb)

KAE609 (Phase IIa)

KAF156 (Phase IIa)

DSM265 (Phase IIa)


MMV048 (Phase I)

Novel chemotypes and new targets

Chemotype and related series	Biological Target	Number of molecules
4-aminoquinolines	Active against CQ-resistant malaria	1 (FQ)
Semi- or fully synthetic peroxides	Active against ART resistance	1 (OZ439)
Diaminopyrimidine	Active against all DHFR resistance	1 (P218)
8-aminoquinoline	Unknown	1 (tafenoquine – single dose)* studies in C21st!
Multiple diverse series	New - ATP4	4 (KAE609, SJ733, GSK030, PA92)
Triazolopyrimidine	New – DHODH	1 (DSM265)
Aminopyridine	New - PI4K	1 (MMV048)
Quinoline	New - to be disclosed	1 (MMV121)
Triaminopyrimidine	New - V-type H ⁺ ATPase	1 (MMV243)
Quinolone	New – bc1 Qi inhibitor	1 (ELQ-300)


New modes of action, overcome historical resistance or single dose

MMV supported projects 1Q 2015



MMV strategic framework to 2018

portfolio | pipeline



MMV is grateful for the support of the following donors

